An update on epidermal growth factor receptor inhibitors.

被引：23

作者：

Modi S. ^{[1
]}

Seidman A.D. ^{[1
]}

机构：

[1] Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, 10021, NY

来源：

Current Oncology Reports | 2002年 / 4卷 / 1期

关键词：

Epidermal Growth Factor Receptor; Ovarian Cancer Cell; Epidermal Growth Factor Receptor Tyrosine Kinase; Human Tumor Xenograft; Epidermal Growth Factor Receptor Activation;

D O I：

10.1007/s11912-002-0047-6

中图分类号：

学科分类号：

摘要：

The epidermal growth factor receptor (EGFR) is part of a family of plasma membrane receptor tyrosine kinases that control many important cellular functions, from cell growth and proliferation to cell death. Dysregulation of the EGFR signal transduction pathway has been implicated in tumorigenesis and cancer progression, making it a clinically relevant target for novel anticancer treatments. This paper reviews recent progress in the development of cancer therapies that are directed toward particular aspects of the extracellular and intracellular domains of EGFR. Promising new compounds in the advanced stages of clinical testing are emphasized.

引用

页码：47 / 55

页数：8

共 152 条

[1]

Prenzel N(2001)The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification Endocr Relat Cancer 8 11-31

[2]

Fischer OM(1990)Signal transduction by receptors with tyrosine kinase activity Cell 61 203-212

[3]

Streit S(1999)The epidermal growth factor receptor and its inhibition in cancer therapy Pharmacol Therap 82 241-250

[4]

Ullrich A(1995)Epidermal growth factor-related peptides and their receptors in human malignancies Crit Rev Oncol Hematol 19 183-232

[5]

Schlessinger J(2001)The epidermal growth factor receptor as a target for cancer therapy Endocr Relat Cancer 8 3-9

[6]

Woodburn JR(1991)Phase I and imaging trial of indium-111 labeled anti-EGF receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma J Natl Cancer Inst 83 97-104

[7]

Salomon DS(1995)Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model Clin Cancer Res 1 1311-1318

[8]

Brandt R(2001)The Willet F. Whitmore Jr, Lectureship: Blockade of epidermal growth factor receptors as anticancer therapy J Urol 165 1152-1157

[9]

Ciardiello F(2001)C225 anti-EGFR antibody potentiates radiation and chemotherapy cytotoxicity in human non-small cell lung cancer cells in vitro and in vivo [abstract] Proc ASCO 20 257a-257a

[10]

Mendelsohn J(2000)Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin J Clin Oncol 18 904-914

← 1 2 3 4 5 6 7 8 9 10 →